

Top 20: SOUTH KOREA - Registers 5% Growth

07 July 2014 | Analysis | By BioSpectrum Bureau





South Korean publicly listed bioscience companies in 2013 registered combined revenue of \$8.3 billion.

The leading publicly listed bioscience company in South Korea, Yuhan Corporation, clocked \$825.6 million in revenue.

Some of the key developments in the country included:

Merck and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, expanded collaboration to develop, manufacture and commercialize MK-1293

Korea and Singapore scientists jointly studied RUNX3, a gene that is intensively studied for its function as a tumour suppressor, and analysed that it is also likely to be a key and critical component of the body's first line of defence against lung cancer development.

Daegu Gyeongbuk Institute of Science and Technology (DGIST) collaborated with Agilent Technologies to launch DGIST's new Neurometabolomics Excellence Research Center for early detection and diagnosis of brain diseases.

The government implemented new policies giving tax breaks for research and development costs and established a R&D fund for the pharmaceutical market.

SOUTH KOREA: TOP 20 BIOSCIENCE COMPANIES

Rank	Company	Revenue		
		CY 2013 (\$M)	CY 2012 (\$M)	Change over 2012
1	Yuhan Corporation	825.6	679.4	22%
2	Green Cross	777.1	710.2	9%
3	Hanmi Holdings (formerly Hanmi Pharmaceutical)	638.8	589.7	8%
4	Daewoong Pharmaceutical	597.2	585.3	2%
5	Dong-A Social Holdings	499.5	424.2	18%
6	Chong Kun Dang Holdings	490.4	521.0	-6%
7	Jeil Pharmaceutical	395.4	373.4	6%
8	LG Life Sciences	365.2	355.2	3%
9	ILDong Pharmaceutical*	345.8	317.4	9%
10	JW Pharmaceutical (Formerly known as Choongwae Pharma)	344.9	347.4	-1%
11	Handok Inc	286.9	275.3	4%
12	Boryung Pharmaceutical	286.3	273.0	5%
13	Celltrion	197.9	306.4	-35%
14	Dongwha Pharm	192.7	195.4	-1%
15	Shin Poong Pharmaceutical	189.0	193.5	-2%
16	Daewon Pharmaceutical	139.0	120.9	15%
17	Huons Company	138.4	117.3	18%
18	Yungjin Pharm	137.0	120.5	14%
19	Ahn -Gook Pharmaceutical	134.8	123.2	9%
20	Korea United Pharm	119.8	118.0	2%
* Revenue of listed companies only				